Taimur Sher, M.B.B.S., M.D.

  1. Hematologist
  2. Internist
  3. Oncologist
  1. Ailawadhi S, Adu Y, Frank RD, Das S, Hodge DO, Fernandez A, Flott C, Elliott J, Parrondo R, Sher T, Roy V, Chanan-Khan AA. Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities. Blood Cancer J. 2024 May 28; 14 (1):86
    View PubMed
  2. Parrondo RD, Dutta N, LaPlant BR, Elliott J, Fernandez A, Zimmerman A, Cicco G, Han B, Heslop K, Chapin D, Sher T, Roy V, Rasheed A, Das S, Chanan-Khan AA, Paulus A, Ailawadhi S. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2024 May; 204 (5):1825-1829 Epub 2024 Jan 29
    View PubMed
  3. Alhaj Moustafa M, Parrondo R, Abdulazeez MF, Roy V, Sher T, Alegria VR, Warsame RM, Fonseca R, Rasheed A, Gonsalves WI, Kourelis T, Kapoor P, Buadi FK, Dingli D, Hayman SR, Reeder CB, Chanan-Khan AA, Ailawadhi S. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. Anticancer Drugs. 2024 Jan 1; 35 (1):63-69 Epub 2023 Apr 06
    View PubMed
  4. Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, Jevremovic D, Buadi FK, Dingli D, Lacy MQ, Fonseca R, Bergsagel PL, Ailawadhi S, Roy V, Parrondo R, Sher T, Hayman SR, Kapoor P, Leung N, Cook J, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Lin Y, Seth A, Lester SC, Breen WG, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023 Nov 30; 142 (22):1871-1878
    View PubMed
  5. Das S, Ailawadhi S, Sher T, Roy V, Fernandez A, Parrondo RD. Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety. Curr Oncol. 2023 Oct 31; 30 (11):9627-9633
    View PubMed
  6. Yassine F, Kharfan-Dabaja MA, Tsalantsanis A, Roy V, Zubair AC, Murthy HS, Ayala E, Iqbal M, Sher T, Ailawadhi S, Parrondo RD. Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience. Bone Marrow Transplant. 2023 Oct; 58 (10):1130-1136 Epub 2023 July 21
    View PubMed
  7. Aslam FN, Manochakian R, Lou Y, Colon-Otero G, Sher T. Trends in participant race and sex reporting in lung cancer phase III clinical trials. Cancer Rep (Hoboken). 2023 Sep; 6 Suppl 1 (Suppl 1):e1856 Epub 2023 July 08
    View PubMed
  8. Ailawadhi S, Ailawadhi M, Dutta N, Parrondo RD, Roy V, Sher T, Baksh M, Rasheed A, Das S, Fernandez AJ, Paulus A, Chanan-Khan AA. The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers. Cancer Med. 2023 Sep; 12 (18):19013-19020 Epub 2023 Aug 17
    View PubMed
  9. Ailawadhi S, Parrondo RD, Dutta N, Han B, Ciccio G, Cherukuri Y, Alegria VR, LaPlant BR, Roy V, Sher T, Edwards B, Lanier S, Manna A, Heslop K, Caulfield T, Maldosevic E, Storz P, Manochakian R, Asmann Y, Chanan-Khan AA, Paulus A. AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma. Cancers (Basel). 2023 Jan 12; 15 (2)
    View PubMed
  10. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023 Jan; 98 (1):49-55 Epub 2022 Oct 24
    View PubMed
  11. Niazi SK, Iqbal M, Spaulding AC, Wood C, Manochakian R, Paulus A, Ailawadhi S, Brennan E, Kharfan Dabaja MA, Sher T. Impact of Benzodiazepine Use on Length of Stay and 30-Day ED Visits among Hospitalized Hematopoietic Stem Cell Transplant Recipients. South Med J. 2022 Dec; 115 (12):936-943
    View PubMed
  12. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan AA, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. Blood. 2022 Nov 3; 140 (18):1997-2000
    View PubMed
  13. Ailawadhi S, Parrondo RD, Moustafa MA, LaPlant BR, Alegria V, Chapin D, Roy V, Sher T, Paulus A, Chanan-Khan AA. Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Hematol Oncol. 2022 Oct; 40 (4):695-703 Epub 2022 May 08
    View PubMed
  14. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Chanan-Khan AA, Kenderian SS, Muchtar E, Wang Y, Ailawadhi S, Koehler AB, Parrondo R, Schwager SM, Sher T, Hanson CA, Shi M, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022 Sep 1; 12 (9):124 Epub 2022 Sept 01
    View PubMed
  15. Singh A, Al-Kali A, Begna KH, Litzow MR, Larsen JT, Sher T, Abdelmagid MG, Farrukh F, Reichard KK, Gangat N, Pardanani A, Tefferi A. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. Am J Hematol. 2022 May; 97 (5):630-637 Epub 2022 Feb 22
    View PubMed
  16. Kase AM, Kharfan-Dabaja MA, Donaldson A, Elliott J, Sher T. Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR-T. Clin Case Rep. 2022 Apr; 10 (4):e05572 Epub 2022 Apr 08
    View PubMed
  17. Ailawadhi S, Swaika A, Advani P, Hodge D, Paulus A, Khera N, Hashmi SK, Alegria VR, Abdulazeez M, Bodepudi S, Jamwal K, Roy V, Sher T, Chanan-Khan A, Ailawadhi M. Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study. J Oncol Pharm Pract. 2022 Mar; 28 (2):425-433 Epub 2021 Mar 09
    View PubMed
  18. Baksh M, Li K, Jiang L, Alegria V, Sher T, Roy V, Chanan-Khan A, Ailawadhi S, Parrondo RD, Alhaj Moustafa M. Myelomatous ascites and pleural effusion in relapsed multiple myeloma. Clin Case Rep. 2022 Feb; 10 (2):e05329 Epub 2022 Feb 02
    View PubMed
  19. Vaxman I, Abeykoon J, Dispenzieri A, Kumar SK, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Reeder C, Sher T, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Go R, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Kristen M, Kapoor P, Gertz MA. "Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. Blood Cancer J. 2021 Dec 7; 11 (12):196 Epub 2021 Dec 07
    View PubMed
  20. Baksh M, Jiang L, Bhatia U, Alegria V, Sher T, Roy V, Chanan-Khan A, Ailawadhi S, Parrondo RD. Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature. Clin Case Rep. 2021 Dec; 9 (12):e05181 Epub 2021 Dec 07
    View PubMed
  21. Jayakrishnan T, Aulakh S, Baksh M, Nguyen K, Ailawadhi M, Samreen A, Parrondo R, Sher T, Roy V, Manochakian R, Paulus A, Chanan-Khan A, Ailawadhi S. Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting. Cancers (Basel). 2021 Nov 18; 13(22).
    View PubMed
  22. Aslam N, Trautman CL, Sher T. Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance. Transplant Direct. 2021 Aug; 7 (8):e723 Epub 2021 July 09
    View PubMed
  23. Abeykoon JP, Zanwar S, Ansell SM, Muchtar E, He R, Greipp PT, King RL, Ailawadhi S, Paludo J, Larsen JT, Habermann TM, Inwards D, Go RS, Thanarajasingam G, Buadi F, Dispenzieri A, Thompson CA, Witzig TE, Lacy M, Gonsalves W, Nowakowski GS, Dingli D, Rajkumar SV, Kyle RA, Sher T, Roy V, Rosenthal A, Chanan-Khan AA, Reeder C, Gertz MA, Kumar S, Kapoor P. Assessment of fixed-duration therapies for treatment-naive Waldenstrom macroglobulinemia. Am J Hematol. 2021 Aug 1; 96 (8):945-953 Epub 2021 May 22
    View PubMed
  24. Saifi O, Lester SC, Rule W, Stish BJ, Stafford S, Pafundi DH, Jiang L, Menke D, Moustafa MA, Rosenthal A, Sher T, Ernesto A, Tun HW, Hoppe BS, Peterson JL. Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. Adv Radiat Oncol. 2021 Jul-Aug; 6 (4):100714 Epub 2021 May 08
    View PubMed
  25. Iqbal M, Castano YG, Sher T, Kharfan-Dabaja MA. Intraocular involvement of Mantle cell lymphoma: A case report and literature review. Hematol Oncol Stem Cell Ther. 2021 Jun; 14 (2):147-152 Epub 2019 Apr 06
    View PubMed
  26. Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, Lacy MQ, Dingli D, Ailawadhi S, Bergsagel PL, Fonseca R, Hayman SR, Kapoor P, Grogan M, Abou Ezzeddine OF, Rosenthal JL, Mauermann M, Siddiqui M, Gonsalves WI, Kourelis TV, Larsen JT, Reeder CB, Warsame R, Go RS, Murray DL, McPhail ED, Dasari S, Jevremovic D, Kyle RA, Lin Y, Lust JA, Russell SJ, Hwa YL, Fonder AL, Hobbs MA, Rajkumar SV, Roy V, Sher T. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc. 2021 Jun; 96(6):1546-1577.
    View PubMed
  27. Sher T. Silence in the Noise: Journey With Hearing Loss Across 2 Worlds. Mayo Clin Proc. 2021 May; 96 (5):1132-1134 Epub 2021 Apr 09
    View PubMed
  28. Parrondo RD, Moustafa MA, Reeder C, Sher T, Roy V, Muchtar E, Warsame R, Alegria V, Gonsalves W, Dingli D, Hayman S, Kapoor P, Chanan-Khan AA, Ailawadhi S. Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2021 May; 21 (5):355-360 Epub 2021 Jan 12
    View PubMed
  29. Kumar V, Ailawadhi M, Dutta N, Abdulazeez M, Aggarwal CS, Quintero G, Baksh M, Roy V, Sher T, Alegria V, Paulus A, Chanan-Khan A, Ailawadhi S. Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. Clin Lymphoma Myeloma Leuk. 2021 May; 21 (5):e449-e455 Epub 2020 Dec 24
    View PubMed
  30. Ailawadhi S, Frank R, Ailawadhi M, Kanji Z, Jani P, Fiala M, Abdulazeez M, Ahmed S, Aggarwal CS, Aulakh S, Hodge D, Roy V, Alegria VR, Paulus A, Chanan-Khan A, Sher T. Utilization of radiation therapy in multiple myeloma: trends and changes in practice. Ann Hematol. 2021 Mar; 100 (3):735-741 Epub 2021 Jan 12
    View PubMed
  31. Khokhar A, Spaulding A, Niazi Z, Ailawadhi S, Manochakian R, Chanan-Khan A, Niazi S, Sher T. A Panel Evaluation of the Changes in the General Public's Social-Media-Following of United States' Public Health Departments during COVID-19 Pandemic. J Prim Care Community Health. 2021 Jan-Dec; 12:2150132721995450
    View PubMed
  32. Parrondo RD, Majeed U, Sher T. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis. Br J Haematol. 2020 Dec; 191 (5):673-681 Epub 2020 May 01
    View PubMed
  33. Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Izquierdo AR, Lossos IS, Reeder C, Sher T, Chen R, Schwarz SE, Alland L, Strassz A, Prier K, Choe-Juliak C, Ansell SM. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020 Nov 19; 136 (21):2401-2409
    View PubMed
  34. Sher T, Stamper GC, Lundy LB. COVID-19 and Vulnerable Population With Communication Disorders. Mayo Clin Proc. 2020 Sep; 95 (9):1845-1847 Epub 2020 June 29
    View PubMed
  35. Sher T, Burger CD, DeMartino ES, de Moraes AG, Sharp RR. Resuscitation and COVID-19: Recalibrating Patient and Family Expectations During a Pandemic. Mayo Clin Proc. 2020 Sep; 95 (9):1848-1851 Epub 2020 June 29
    View PubMed
  36. Sher T, Velarde GP, Gertz MA. V122I Transthyretin Cardiomyopathy: An Opportunity to Build Trust and Resolve Disparities. J Am Coll Cardiol. 2020 Jul 7; 76 (1):93-95
    View PubMed
  37. Iqbal M, Spaulding A, Niazi S, Wood C, Ahmed S, Jani P, Kharfan-Dabaja MA, Ayala E, Manochakian R, Ames S, Paulus A, Ailawadhi S, Roy V, Chanan-Khan A, Sher T. Impact of Depression and Anxiety on Opioid Use in Hospitalized Hematopoietic Cell Transplantation Recipients. Psychosomatics. 2020 Jul - Aug; 61 (4):363-370 Epub 2020 Mar 26
    View PubMed
  38. Sher T, Wright RS. Public Health Crises and the Human Subjects of Biomedical Research: A Focus on COVID-19. Mayo Clin Proc. 2020 Jun; 95 (6):1130-1131 Epub 2020 Apr 20
    View PubMed
  39. Manna A, Kellett T, Aulakh S, Lewis-Tuffin LJ, Dutta N, Knutson K, Chini E, Pinilla-Ibarz J, Lamanna N, Manochakian R, Malavasi F, Sher T, Chanan-Khan AA, Ailawadhi S, Paulus A. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Adv. 2020 May 26; 4 (10):2143-2157
    View PubMed
  40. Kumar V, Alhaj-Moustafa M, Bojanini L, Sher T, Roy V, Manochakian R, Vishnu P, Bodepudi S, Shareef Z, Ahmed S, Jani P, Paulus A, Grover A, Alegria VR, Ailawadhi M, Chanan-Khan A, Ailawadhi S. Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. JCO Oncol Pract. 2020 Apr; 16 (4):e341-e349 Epub 2020 Jan 21
    View PubMed
  41. Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. JCO Oncol Pract. 2020 Feb; 16 (2):56-66
    View PubMed
  42. Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS, Mayo Clinic Histiocytosis Working Group. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020; 105 (2):348-357 Epub 2020 Jan 31
    View PubMed
  43. Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, Foran J, Tun H, Kumar A, Kharfan-Dabaja MA. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2020 Jan; 26 (1):76-82 Epub 2019 Sept 05
    View PubMed
  44. Al Saleh AS, Sher T, Gertz MA. Multiple Myeloma in the Time of COVID-19. Acta Haematol. 2020; 143 (5):410-416 Epub 2020 Apr 17
    View PubMed
  45. Parrondo RD, Roy V, Sher T, Alegria V, Chanan-Khan AA, Ailawadhi S. Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review. Case Rep Hematol. 2020; 2020:4360926 Epub 2020 Feb 18
    View PubMed
  46. Valery JR, Applewhite A, Manaois A, Dimuna J, Sher T, Heckman MG, Brushaber DE, Stancampiano F. A Retrospective Analysis of Gender-Based Difference in Adherence to Initial Colon Cancer Screening Recommendations. J Prim Care Community Health. 2020 Jan-Dec; 11:2150132720931321
    View PubMed
  47. Iqbal M, Reljic T, Klocksieben F, Sher T, Ayala E, Murthy H, Bazarbachi A, Kumar A, Kharfan-Dabaja MA. Corrigendum to 'Efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis' [Biology of Blood and Marrow Transplantation 25/8 (2019) 1695-1700]. Biol Blood Marrow Transplant. 2020 Jan; 26 (1):209-212 Epub 2019 Oct 11
    View PubMed
  48. Applewhite A, Stancampiano FF, Harris DM, Manaois A, Dimuna J, Glenn J, Heckman MG, Brushaber DE, Sher T, Valery JR. A Retrospective Analysis of Gender-Based Difference in Adherence to Influenza Vaccination during the 2018-2019 Season. J Prim Care Community Health. 2020 Jan-Dec; 11:2150132720958532
    View PubMed
  49. Melody M, Butts E, Menke D, Landolfo K, Oken K, Sher T, Khurana S. Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction. Leuk Res Rep. 2020; 14:100228 Epub 2020 Nov 04
    View PubMed
  50. Ailawadhi S, Azzouqa AG, Hodge D, Cochuyt J, Jani P, Ahmed S, Sher T, Roy V, Ailawadhi M, Alegria VR, Manochakian R, Vishnu P, Grover A, Abdulazeez MF, Paulus A, Chanan-Khan A. Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities. Clin Lymphoma Myeloma Leuk. 2019 Oct; 19 (10):619-623 Epub 2019 June 26
    View PubMed
  51. Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T, Roy V, Vishnu P, Marin-Acevedo J, Alegria VR, Paulus A, Aulakh S, Iqbal M, Manochakian R, Tan W, Chanan-Khan A, Ailawadhi M. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019 Sep 30; 9 (10):75 Epub 2019 Sept 30
    View PubMed
  52. Ailawadhi S, Sher T, Azzouqa AG, Meghji Z, Jain T, Jani P, Ahmed S, Diehl N, Roy V, Shah V, Hodge D, Ailawadhi M, Alegria VR, Paulus A, Chanan-Khan A, Fonseca R. Monoclonal antibody utilization characteristics in patients with multiple myeloma. Anticancer Drugs. 2019 Sep; 30 (8):859-865
    View PubMed
  53. Iqbal M, Reljic T, Klocksieben F, Sher T, Ayala E, Murthy H, Bazarbachi A, Kumar A, Kharfan-Dabaja MA. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis. Biol Blood Marrow Transplant. 2019 Aug; 25 (8):1695-1700 Epub 2019 May 25
    View PubMed
  54. Manna A, Aulakh S, Jani P, Ahmed S, Akhtar S, Coignet M, Heckman M, Meghji Z, Bhatia K, Sharma A, Sher T, Alegria V, Malavasi F, Chini EN, Chanan-Khan A, Ailawadhi S, Paulus A. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2019 Jul 1; 25 (13):3974-3985 Epub 2019 Apr 02
    View PubMed
  55. Ailawadhi S, Dholaria BR, Khurana S, Sher T, Alegria V, Paulus A, Ailawadhi M, Mehta A, Chanan-Khan A, Roy V. Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. Br J Haematol. 2019 Apr; 185 (2):347-350 Epub 2018 July 05
    View PubMed
  56. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019 Mar; 54 (3):353-367 Epub 2018 July 09
    View PubMed
  57. Ailawadhi S, Kelly KR, Vescio RA, Jagannath S, Wolf J, Gharibo M, Sher T, Bojanini L, Kirby M, Chanan-Khan A. A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Jan; 19 (1):29-34 Epub 2018 Sept 05
    View PubMed
  58. Iqbal M, Jani P, Ahmed S, Sher T. First Report of Hereditary Lysozyme Amyloidosis in a South Asian Family. Case Rep Hematol. 2019; 2019:5092496 Epub 2019 Feb 10
    View PubMed
  59. Parrondo RD, Sher T. Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma. Onco Targets Ther. 2019; 12:8467-8478 Epub 2019 Oct 14
    View PubMed
  60. Dholaria BR, Hammond WA, Roy V, Sher T, Vishnu P, Soyano A, Finn LE, Tun H. Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. Leuk Lymphoma 2018 Nov; 59 (11):2727-2730 Epub 2018 Mar 23
    View PubMed
  61. Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, Jiang L, Roy V, Witzig TE, Ansell SM, Allan J, Furman R, Aulakh S, Manochakian R, Ailawadhi S, Chanan-Khan AA, Sher T. Targeting CD38 with daratumumab is lethal to Waldenstrom macroglobulinaemia cells. Br J Haematol. 2018 Oct; 183 (2):196-211 Epub 2018 Aug 06
    View PubMed
  62. Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM. Phase 1 study of the PI3Kdelta inhibitor INCB040093 +/- JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood. 2018 Jul 19; 132 (3):293-306 Epub 2018 Apr 25
    View PubMed
  63. Niazi S, Frank RD, Sharma M, Roy V, Ames S, Rummans T, Spaulding A, Sher T, Ailawadhi M, Bhatia K, Ahmed S, Tan W, Chanan-Khan A, Ailawadhi S. Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. Blood Adv. 2018 May 22; 2 (10):1120-1128
    View PubMed
  64. Ailawadhi S, Frank RD, Sharma M, Menghani R, Temkit M, Paulus S, Khera N, Hashmi S, Advani P, Swaika A, Paulus A, Aslam N, Sher T, Roy V, Colon-Otero G, Chanan-Khan A. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. Cancer. 2018 Apr 15; 124 (8):1710-1721 Epub 2018 Jan 23
    View PubMed
  65. Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia. 2018 Mar; 32 (3):719-728 Epub 2017 Sept 01
    View PubMed
  66. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7; 130 (10):1198-1204 Epub 2017 July 06
    View PubMed
  67. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1; 3 (9):1257-1265
    View PubMed
  68. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017 Apr; 92 (4):578-598 Epub 2017 Mar 11
    View PubMed
  69. Sher T, Gertz MA. Stem cell transplantation for immunoglobulin light chain amyloidosis. Curr Probl Cancer. 2017 Mar - Apr; 41 (2):129-137 Epub 2017 Mar 16
    View PubMed
  70. Sher T, Fenton B, Akhtar A, Gertz MA. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood 2016 Oct 13; 128 (15):1987-1989 Epub 2016 Aug 19
    View PubMed
  71. Kaleem T, Crozier JA, Menke DM, Sher T. Post-Transplant Lymphoproliferative Disorder Presenting as CD20-Negative Plasmablastic Lymphoma in the Lung. Rare Tumors. 2016 Sep 5; 8 (3):6220 Epub 2016 Sept 05
    View PubMed
  72. Sher T, Dispenzieri A, Gertz MA. Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biol Blood Marrow Transplant. 2016 May; 22: (5)796-801.
    View PubMed
  73. Sher T, Gertz MA. Antibody based immunotherapy for multiple myeloma: it's about time. Leuk Lymphoma. 2016 Feb; 57 (2):269-275 Epub 2015 Dec 16
    View PubMed
  74. Sher T, Gertz MA. Antibody based immunotherapy for multiple myeloma: it's about time Leukemia & Lymphoma. 2016 Feb 1; 57: (2)269-75.
  75. Crozier JA, Sher T, Yang D, Swaika A, Foran J, Ghosh R, Tun H, Colon-Otero G, Kelly K, Chanan-Khan A, Ailawadhi S. Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. Clin Lymphoma Myeloma Leuk. 2015 Oct; 15 (10):578-85 Epub 2015 June 19
    View PubMed
  76. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81.
    View PubMed
  77. Chitta K, Paulus A, Akhtar S, Blake MK, Caulfield TR, Novak AJ, Ansell SM, Advani P, Ailawadhi S, Sher T, Linder S, Chanan-Khan A. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. Br J Haematol. 2015 May; 169(3):377-90. Epub 2015 Feb 17.
    View PubMed
  78. Swaika A, Menke DM, Jain MK, Sher T. Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type. Ann Hematol 2015 May; 94 (5):895-6 Epub 2014 Nov 15
    View PubMed
  79. Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015 Feb; 12 (2):91-102 Epub 2014 Oct 14
    View PubMed
  80. Andhavarapu S, Crozier JA, Jiang L, Sher T. Mantle cell lymphoma and diffuse large B-cell lymphoma of the testis: a unique case of composite non-Hodgkin lymphoma. Eur J Haematol. 2014 Dec; 93(6):537-42. Epub 2014 May 22.
    View PubMed
  81. Crozier JA, Andhavarapu S, Brumble LM, Sher T. First report of Nocardia beijingensis infection in an immunocompetent host in the United States. J Clin Microbiol. 2014 Jul; 52 (7):2730-2 Epub 2014 May 14
    View PubMed
  82. Chitta KS, Khan AN, Ersing N, Swaika A, Masood A, Paulus A, Qadeer A, Advani P, Sher T, Miller KC, Lee K, Chanan-Khan AA. Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells. Leuk Lymphoma. 2014 Mar; 55: (3)652-61.
    View PubMed
  83. Sher T, Gertz MA. Recent advances in the diagnosis and management of cardiac amyloidosis. Future Cardiol. 2014 Jan; 10(1):131-46.
    View PubMed
  84. Sher T, Bhat S, Jitawatanarat P, Desai N, Qiu J, Ma WW. Multiple myeloma mimicking metastatic pancreas cancer. J Clin Oncol. 2013 Jun 20; 31 (18):e297-9 Epub 2013 May 13
    View PubMed
  85. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88 (4):360-76
    View PubMed
  86. Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, Masood A, Sher T, Miller KC, Iancu DM, Conroy J, Nowak NJ, Sait SN, Personett DA, Coleman M, Furman RR, Martin P, Ansell SM, Lee K, Chanan-Khan AA. Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenstrom Macroglobulinemia 1. Leuk Lymphoma. 2013 Feb; 54 (2):387-96 Epub 2012 Aug 27
    View PubMed
  87. Sher T, Gertz M A. Recent Advances in the Diagnosis and Management of Cardiac Amyloidosis Future Cardiology. 2013 (in press).
  88. Sher T, Hayman SR, Gertz MA. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy. Clin Adv Hematol Oncol. 2012 Oct; 10 (10):644-51
    View PubMed
  89. Kasyapa CS, Sher T, Chanan-Khan AA. Multiple myeloma and immunomodulation: regulating the regulatory cells. Leuk Lymphoma. 2012 Jul; 53 (7):1253-4 Epub 2012 Apr 03
    View PubMed
  90. Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol. 2012 Jul-Aug; 10: (4)155-9.
    View PubMed
  91. Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, Chanan-Khan A. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012 Jul; 158(1):91-8. Epub 2012 Apr 26.
    View PubMed
  92. Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A. Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Jun; 53(6):1174-82. Epub 2011 Dec 6
    View PubMed
  93. Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol. 2012 Apr; 157: (1)59-66.
    View PubMed
  94. Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011 Nov; 155: (4)457-67.
    View PubMed
  95. Masood A, Sher T, Chanan-Khan A. Reply to tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts response. Cancer. 2011 Aug 31.
  96. Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, Iancu D, Lee K, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol. 2011 Jul; 154(1):104-10. Epub 2011 May 09.
    View PubMed
  97. Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2011 Jun; 7: (6)765-74.
    View PubMed
  98. Paulus A, Masood A, Advani P, Sher T, Chitta K, Chanan-Khan A. Elotuzumab, a humanized monoclonal antibody against the CD2 cell surface glycoprotein CS1 for the treatment of multiple myeloma Thomson Reuters Drug Profiles. 2011.
  99. Masood A, Sher T, Paulus A, Miller KC, Chitta KS, Chanan-Khan A. Targeted treatment for chronic lymphocytic leukemia. Onco Targets Ther. 2011; 4:169-83.
    View PubMed
  100. Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol. 2010 Aug; 150(4):418-27.
    View PubMed
  101. Baz R, Patel M, Finley-Oliver E, Lebovic D, Hussein MA, Miller KC, Wood M, Sher T, Lee K, Chanan-Khan AA. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma. 2010 Jun; 51(6):1015-9.
    View PubMed
  102. Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, Miller A, Lawrence W, Bilgrami SA, Sood R, Wood MT, Block AW, Lee K, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010 Jan; 51(1):85-8.
    View PubMed
  103. Sher T, Miller KC, Lee K, Chanan-Khan A. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Clin Lymphoma Myeloma. 2009 Aug; 9 (4):328-30
    View PubMed
  104. Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma. 2009 Jul; 50(7):1096-101.
    View PubMed
  105. Sher T, Miller K, Lee K, Chanan-Khan A. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Clin Lymphoma Myeloma. 2009; 9(4):328-30.
  106. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008 Mar; 83 (3):355-67
    View PubMed
  107. Sher T, Hennessy BT, Valero V, Broglio K, Woodward WA, Trent J, Hunt KK, Hortobagyi GN, Gonzalez-Angulo AM. Primary angiosarcomas of the breast. Cancer. 2007 Jul 1; 110 (1):173-8
    View PubMed
  108. Rao S, Sivina M, Willis I, Sher T, Habibnejad S. Massive lower gastrointestinal tract bleeding due to splenic artery aneurysm: a case report. Ann Vasc Surg. 2007 May; 21 (3):388-91
    View PubMed